Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.7400 (-1.06%) ($3.7000 - $3.7400) on Thu. Jan. 27, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.11% (three month average) | RSI | 15 | Latest Price | $3.7400(-1.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.8% a day on average for past five trading days. | Weekly Trend | AUTL declines -9.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(64%) IBB(59%) IBUY(56%) ARKG(52%) ARKK(52%) | Factors Impacting AUTL price | AUTL will decline at least -2.555% in a week (0% probabilities). VIXM(-41%) VXX(-33%) TIP(-25%) TLT(-24%) SHY(-22%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.555% (StdDev 5.11%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-17.48(-567.38%) | Resistance Level | $4.47 | 5 Day Moving Average | $3.84(-2.6%) | 10 Day Moving Average | $4.03(-7.2%) | 20 Day Moving Average | $4.47(-16.33%) | To recent high | -46.9% | To recent low | 0% | Market Cap | $195m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |